Combination of an oral H2S donor to dapagliflozin provides additional therapeutic benefit in a cardiorenal model of heart failure with preserved ejection fraction (HFpEF)
Event: ESC Congress 2025
Topic: Heart Failure
Session: Metabolic, immune, and cellular drivers of HFpEF pathogenesis and progression
